Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor

Publisher Correction: Oncologists greet Lumakras: the world’s first KRAS inhibitor

Correction to: Nature Biotechnology https://doi.org/101038/ s41587-021-01053 -9, released online 9 September 2021.

In the variation of this News short article at first released, the post ought to have mentioned that in addition to Qiagen’s Therascreen, the FDA likewise authorized Guardant360 CDx from Guardant Health, as buddy diagnostics for Lumakras. In the 4th paragraph, in the 3rd sentence starting “It is authorized for usage with a buddy diagnostic,” completion of the sentence has actually been changed to consist of “or Guardant360 CDx from Guardant Health.”

The online variation of the short article has actually been upgraded.

Author details

Affiliations

  1. Dublin, Ireland

    Cormac Sheridan

Corresponding author

Correspondence to.
Cormac Sheridan.

About this post

Read More

Author: admin